Aripiprazole: A dopamine modulator that mimics methylphenidate in producing faster antidepressant effects

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 183-185

  Chen, Tien Yu ^a   Tzeng, Nian Sheng ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ESCITALOPRAM; METHYLPHENIDATE; PLACEBO;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; FATIGUE; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; NEUROTRANSMISSION; PREDICTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; HUMANS; METHYLPHENIDATE; MODELS, THEORETICAL; PIPERAZINES; QUINOLONES;

EID: 84880039448     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.05.009     Document Type: Article

References (28)

1. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23):3095-3105.
2. Osby U., Brandt L., Correia N., Ekbom A., Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58(9):844-850.
3. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997, 349(9063):1436-1442.
4. Posternak M.A., Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005, 66(2):148-158.
5. Crown W.H., Finkelstein S., Berndt E.R., et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002, 63(11):963-971.
6. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53(8):649-659.
7. Rapaport M.H. Prevalence, recognition, and treatment of comorbid depression and anxiety. J Clin Psychiatry 2001, 62(Suppl 24):6-10.
8. Muzina D.J., Chambers J.S., Camacho T.A., et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care 2011, 17(12):793-801.
9. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70(3):344-353.
10. Lam R.W., Kennedy S.H., Grigoriadis S., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117(Suppl 1):S26-S43.
11. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64(3):327-337.
12. Volkow N.D. Stimulant medications: how to minimize their reinforcing effects?. Am J Psychiatry 2006, 163(3):359-361.
13. Patkar A.A., Masand P.S., Pae C.U., et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006, 26(6):653-656.
14. Candy M., Jones L., Williams R., Tookman A., King M. Psychostimulants for depression. Cochrane Database Syst Rev 2008, 2:CD006722.
15. Leonard B.E., McCartan D., White J., King D.J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004, 19(3):151-180.
16. Kerr C.W., Drake J., Milch R.A., et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 2012, 43(1):68-77.
17. Philip N.S., Carpenter L.L., Tyrka A.R., Price L.H. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract 2008, 14(1):34-44.
18. Weber J., Lyseng-Williamson K.A., Scott L.J. Aripiprazole: in major depressive disorder. CNS Drugs 2008, 22(10):807-813.
19. Pae C.U., Serretti A., Patkar A.A., Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008, 22(5):367-388.
20. Szabo S.T., Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 2001, 922(1):9-20.
21. Grunder G., Carlsson A., Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003, 60(10):974-977.
22. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001, 62(11):841-842.
23. Bristol-Myers Squibb. Abilify: US prescribing information; 2012.
24. Barbee J.G., Conrad E.J., Jamhour N.J. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004, 16(4):189-194.
25. Berman R.M., Marcus R.N., Swanink R., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68(6):843-853.
26. Marcus R.N., McQuade R.D., Carson W.H., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28(2):156-165.
27. Nelson J.C., Thase M.E., Bellocchio E.E., et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol 2012, 27(3):125-133.
28. Katzman M.A. Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. J Affect Disord 2011, 128(Suppl 1):S11-S20.